Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | MLNR | O43193 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170720 | 0.79 | DRD2 (0.47) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL2910834 | 0.76 | CHRM2 (0.38) | HTR2CCDK2CDK5MLNRCYP2D6 | |
| SCHEMBL4181488 | 0.76 | NPC1 (0.47) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL4173286 | 0.75 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL4170763 | 0.72 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL14149272 | 0.71 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL22723818 | 0.71 | DRD3 (0.59) | DRD3DRD2 | |
| SCHEMBL25060963 | 0.70 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL20877646 | 0.70 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL20877621 | 0.70 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| CN-1968931-A | Pyridine analogs as C5A antagonists | MERCK FROSST CANADA LTD (CA) | 2007-05-23 | — | — | CN | disclosed |
| EP-1758865-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121095-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | C5AR2, C5AR1, C3AR1 | ADRA2A 333/4885ADRA2B 351/4885ADRA2C 289/4885 |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | C5AR1, C3AR1, C5AR2 | ADRA2A 479/4885ADRA2B 302/4885ADRA2C 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.